Hoth Therapeutics Announces Positive, Statistically Significant Proof-of-Concept Preclinical Data on its Therapeutic for Cutaneous Lupus Erythematosus (CLE), a Chronic Autoimmune Skin Disease
The study was conducted by Jackson Laboratory in partnership with Zylö Therapeutics
The animal study supports that this drug candidate has the potential to be an effective treatment for cutaneous manifestations of lupus, a significant unmet medical need
Hoth Therapeutics, a biopharmaceutical company, announced positive, statistically significant proof-of-concept preclinical data on its therapeutic HT-005 for the treatment of Cutaneous Lupus Erythematosus (CLE), a chronic autoimmune skin disease.
The study conducted by Jackson Laboratory in partnership with Zylö Therapeutics using a CLE mouse model demonstrated a significant reduction in skin plaque severity after treatment with HT-005-loaded topical Z-pods compared to untreated control mice. The skin severity scoring was based on a semi-quantitative measurement scale of erythema, thickness, scaling, and alopecia measured on the scapula, head, and overall composite score. The study was conducted over the period of 10 weeks and significant reduction of plaque severity in the overall composite score was observed within 3 weeks of treatment and maintained through the entire 10 week treatment cycle, supporting that the therapeutic response is sustained.
Recommended AI News: Vorboss Appoints Volta As Its Core Site To Support Fibre Network Build
“Our final preclinical proof-of-concept data set provides us with optimism in our topical drug candidate for a high unmet need indication, CLE,” stated, Robb Knie, Chairman and CEO of Hoth Therapeutics. “We look forward to working with our partner, Zylö Therapeutics, on the next phase of development of this promising therapeutic.”